Candel Therapeutics, Inc. Stock Price, News & Analysis

Candel Therapeutics (Nasdaq: CADL) presented positive Phase 3 clinical trial results for CAN-2409 in localized prostate cancer at ASTRO 2025. The trial, involving 745 patients with intermediate-to-high-risk localized prostate cancer, demonstrated a 30% improvement in disease-free survival (HR 0.7, p=0.0155) and 38% improvement in prostate cancer-specific disease-free survival (HR 0.62, p=0.0046).

Key findings showed CAN-2409's efficacy was consistent across radiation therapy modalities, with significant improvements observed in both moderate hypofractionated EBRT (HR 0.52) and conventional EBRT (HR 0.76). The treatment achieved 80.4% pathological complete response rates compared to 63.6% in the control arm. Grade ≥3 treatment-related adverse events remained similar between treatment and control groups.

The company plans to submit a Biologics License Application in Q4 2026, positioning CAN-2409 as potentially the first major advancement in localized prostate cancer treatment in over 20 years.

Candel Therapeutics (NASDAQ:CADL) announced the acceptance of their abstract for oral presentation at the 2025 ASTRO Annual Meeting in San Francisco. The presentation will showcase results from their Phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer.

Dr. Glen Gejerman from Hackensack University Medical Center will present the findings of the randomized, placebo-controlled study evaluating CAN-2409+Prodrug in combination with standard EBRT for newly diagnosed localized prostate cancer. The presentation is scheduled for September 28, 2025, at 2:30 PM PT. The abstract has also been selected for ASTRO's Science Highlights - Genitourinary Cancer session.

Candel Therapeutics (Nasdaq: CADL) has appointed renowned immunotherapy pioneer Dr. Carl H. June to its Research Advisory Board. Dr. June, known for developing the first FDA-approved CAR-T cell therapy, will support Candel's advancement of its viral immunotherapy candidates.

Dr. June currently serves as the Richard W. Vague Professor in Immunotherapy at the University of Pennsylvania's Perelman School of Medicine and directs both the Center for Cellular Immunotherapies and Parker Institute for Cancer Immunotherapy. The appointment comes as Candel prepares for a planned BLA submission for CAN-2409 in prostate cancer during Q4 2026.

Candel Therapeutics (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing biological immunotherapies for cancer treatment, announced its participation in three major investor conferences in September 2025.

The company's President and CEO, Dr. Paul Peter Tak, will present at the Citi Biopharma Back to School Conference (September 3), the Cantor Global Healthcare Conference (September 4), and the H.C. Wainwright Global Investment Conference (September 5). All presentations will be available via webcast on the company's website, with replays accessible for up to 90 days.

Candel Therapeutics (NASDAQ:CADL) reported significant Q2 2025 milestones, highlighted by positive phase 3 results for CAN-2409 in prostate cancer showing 30% improvement in disease-free survival versus placebo. The company received FDA RMAT Designation for CAN-2409 in prostate cancer and EMA Orphan Designation for pancreatic cancer treatment.

Financial position remains strong with $100.7 million in cash as of June 30, 2025, expected to fund operations into Q1 2027. The company completed a $15 million registered direct offering in June 2025. Q2 net loss improved to $4.8 million compared to $22.2 million in Q2 2024.

Candel is preparing for BLA submission of CAN-2409 in prostate cancer, expected in Q4 2026, while advancing clinical trials in NSCLC and pancreatic cancer with promising survival data.

Candel Therapeutics (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing biological immunotherapies for cancer treatment, announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's President and CEO, Paul Peter Tak, M.D., Ph.D., FMedSci, will deliver a presentation on August 13, 2025, at 2:00 PM EST in Boston, MA.

The presentation will be accessible via webcast through Candel's investor relations website, with a replay available for up to 90 days after the event.

Candel Therapeutics (Nasdaq: CADL) has received European Medicines Agency (EMA) Orphan Designation for its CAN-2409 treatment for pancreatic cancer. This adds to existing FDA Orphan Drug and Fast Track Designations received in 2024 and 2023.

The company's phase 2a clinical trial demonstrated remarkable results, with median overall survival of 31.4 months in the CAN-2409 plus standard of care arm versus 12.5 months in the control arm. Notably, three of seven treated patients were still alive at data cut-off with survival of 66.0, 63.6, and 35.8 months.

CAN-2409 is an investigational immunotherapy that delivers the HSV-tk gene to tumor cells, potentially inducing systemic immune responses against multiple therapy-resistant solid tumors. The EMA designation provides benefits including reduced fees, protocol assistance, and up to 10 years of market exclusivity if approved.

Candel Therapeutics (Nasdaq: CADL), a clinical-stage biopharmaceutical company, has expanded its presence in Russell indexes following the 2025 Russell US Indexes reconstitution. The company was added to multiple value-oriented indexes including the Russell 2500 Value®, Russell Small Cap Value®, Russell 2000 Value®, Russell Microcap Value®, and Russell 3000E® Value Index, while maintaining its position in the Russell 3000® Index.

This expansion comes at a crucial time as Candel prepares for a potential Biologics License Application for CAN-2409 in intermediate-to-high-risk localized prostate cancer. The company continues to advance its multimodal immunotherapy platform across various solid tumors, focusing on developing biological immunotherapies for cancer treatment.

Candel Therapeutics (Nasdaq: CADL) has announced a $15 million registered direct offering of common stock, selling approximately 3.2 million shares at $4.67 per share to select accredited investors, including healthcare-focused institutional investors and company insiders. The offering is expected to close on June 25, 2025.

The proceeds will support pre-commercialization and launch readiness activities for CAN-2409 in prostate cancer, with a planned Biologics License Application submission in Q4 2026. The participation of existing investors, executives, and board members demonstrates confidence in Candel's approach to treating intractable tumors.